Clinical Trials Logo
  1. Home
  2. SARS-CoV2 Infection
  3. NCT04954651
  4. Details
NCT04954651 Clinical Trial

Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines

SARS-CoV2 Infection Clinical Trial

Official title:
Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received European Union (EU) -Approved COVID-19 Vaccines

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04954651
Other study ID # 99-25/2/2021
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 7, 2021
Est. completion date March 28, 2022

Study information
Verified date June 2022
Source University of Patras
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients who voluntarily visit vaccination centers in Greece against COVID-19 are recruited and their immunization levels against Sars-Cov2 are assesed by measurement of the levels of serum antibodies against Sars-cov-2 before vaccination and in time intervals up to 6-9 months post-vaccination (indicatively 0-1-3-6-9 months post-vaccination).

Recruitment information / eligibility
Status Completed
Enrollment 1000
Est. completion date March 28, 2022
Est. primary completion date March 28, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Subjects who voluntarily receive COVID-19 vaccination Exclusion Criteria: - Patients who do not complete their vaccination - Patients who do not provide info on their health status

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Approved vaccines against Sars-Cov2
Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU

Locations
Country Name City State
Greece University Hospital of Patras Patras

Sponsors (1)
Lead Sponsor Collaborator
University of Patras

Country where clinical trial is conducted

Greece, 

Outcome
Type Measure Description Time frame Safety issue
Primary Antibody titer against Sars-Cov2 0-9 months
See also
  Status Clinical Trial Phase
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Recruiting NCT05311410 - Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures N/A
Active, not recruiting NCT05073718 - SARS-CoV-2 and Acetylsalicylic Acid (SARA) Phase 3
Completed NCT05055492 - The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions N/A
Completed NCT05055505 - The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions N/A
Completed NCT05060510 - The School SPIT Study - COVID-19 Testing in Secondary Schools N/A
Completed NCT05054218 - COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Completed NCT05449392 - Topical Antibacterial Agents for Prevention of COVID-19 Phase 1
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT05172024 - Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
Terminated NCT05593770 - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Phase 2/Phase 3
Completed NCT05030974 - RECOVAC Repeated Vaccination Study Phase 4
Withdrawn NCT05067946 - Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines Phase 2/Phase 3
Not yet recruiting NCT05013034 - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Phase 2
Withdrawn NCT05393999 - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations Phase 2
Recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Not yet recruiting NCT05116657 - Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
Recruiting NCT04590222 - Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Completed NCT04551911 - Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 Phase 2
Completed NCT04953039 - Use of Saliva for COVID-19 Diagnosis